Nordic Life Science 1
The company reports results with its lead candida
te GS-248 for microvascular disease. Gesynta now intends to commence a Martin Jönsson, CEO, AlzeCure Phase II study in patients with Systemic Sclerosis. “The confirmation of strong effects on biomarkers of inflammation and vascular PRE - C LIN I CA L THE FIRST CLINICAL STUDY WITH ACD856 IS AIMING TO EVALUATE HALF-LIFE IN HUMANS. ACD856 IS CURRENTLY under development for diseases such as Alzheimer’s disease. The results have demonstrated that ACD856, the lead drug candidate within the company’s NeuroRestore platform, has a good pharmacokinetic profile with a significantly shorter human halflife than its predecessor ACD855, as well as a suitability for further clinical development, e.g. in oral treatment of Alzheimer’s disease. AlzeCure Pharma initiated the study in December 2019 and has now presented the results of this first clinical study with ACD856 according to plan. Preparations are ongoing to initiate further clinical trials, with a planned start by the end of 2020. These upcoming Phase I studies are aimed at evaluating tolerability in humans, as well as early efficacy signals. “Due to the fact that AlzeCure is not centered around one single drug candidate, a quick follow-up strategy is possible, while also opening up opportunities for multiple indications,” says Martin Jönsson, CEO of AlzeCure. “This will also stimulate potential partnership and out-licensing discussions, as well as increase interest in the NeuroRestore platform.” protection in humans demonstrates the potential of GS248 as a unique treatment of microvascular dysfunction in Systemic Sclerosis and other chronic inflammatory conditions. We now intend to initiate a multicenter Phase IIa study with enrollment commencing in Q4, 2020,” says Patric Stenberg, CEO of Gesynta Pharma. ”WE NOW INTEND TO INITIATE A MULTICENTER PHASE IIA STUDY WITH ENROLLMENT COMMENCING IN Q4, 2020”